FDG-PET/CT in colorectal cancer: potential for vascular-metabolic imaging to provide markers of prognosis
| Autor: | Sherif Raouf, Stuart A. Taylor, Tony Ng, Balaji Ganeshan, Aman Bhargava, Tan Arulampalam, Nicholas Reay-Jones, Shahab Siddiqi, Bruce Sizer, Kenneth A. Miles, Raymond Endozo, Francesco Fraioli, Ashley M. Groves, Shih-hsin Chen, Michael Machesney, Darren Walls, Sanjay Dindyal, Joseph Huang, Luke Hoy, Robert Shortman, Simon Wan, Daren Francis, Asim Afaq, Manuel Rodriquez, Matthew Hanson |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Survival Colorectal cancer Perfusion scanning Gastroenterology 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Fluorodeoxyglucose F18 Internal medicine Vascular Positron Emission Tomography Computed Tomography medicine Humans Radiology Nuclear Medicine and imaging Stage (cooking) FDG-PET Aged Retrospective Studies Fluorodeoxyglucose business.industry Metabolic imaging Hazard ratio Correction General Medicine Blood flow Middle Aged medicine.disease Prognosis Tumor Burden Metabolism 030220 oncology & carcinogenesis Positron-Emission Tomography CT perfusion Original Article Female Radiopharmaceuticals business Colorectal Neoplasms Perfusion Glycolysis medicine.drug |
| Zdroj: | Eur J Nucl Med Mol Imaging European Journal of Nuclear Medicine and Molecular Imaging |
| ISSN: | 1619-7089 |
| Popis: | Purpose This study assesses the potential for vascular-metabolic imaging with FluoroDeoxyGlucose (FDG)–Positron Emission Tomography/Computed Tomography (PET/CT) perfusion to provide markers of prognosis specific to the site and stage of colorectal cancer. Methods This prospective observational study comprised of participants with suspected colorectal cancer categorized as either (a) non-metastatic colon cancer (M0colon), (b) non-metastatic rectal cancer (M0rectum), or (c) metastatic colorectal cancer (M+). Combined FDG-PET/CT perfusion imaging was successfully performed in 286 participants (184 males, 102 females, age: 69.60 ± 10 years) deriving vascular and metabolic imaging parameters. Vascular and metabolic imaging parameters alone and in combination were investigated with respect to overall survival. Results A vascular-metabolic signature that was significantly associated with poorer survival was identified for each patient group: M0colon – high Total Lesion Glycolysis (TLG) with increased Permeability Surface Area Product/Blood Flow (PS/BF), Hazard Ratio (HR) 3.472 (95% CI: 1.441–8.333), p = 0.006; M0rectum – high Metabolic Tumour Volume (MTV) with increased PS/BF, HR 4.567 (95% CI: 1.901–10.970), p = 0.001; M+ participants, high MTV with longer Time To Peak (TTP) enhancement, HR 2.421 (95% CI: 1.162–5.045), p = 0.018. In participants with stage 2 colon cancer as well as those with stage 3 rectal cancer, the vascular-metabolic signature could stratify the prognosis of these participants. Conclusion Vascular and metabolic imaging using FDG-PET/CT can be used to synergise prognostic markers. The hazard ratios suggest that the technique may have clinical utility. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink